Please remember the rest of the world is up Covid creek.
I think the NZ sales are really important. First, its a country with no COVID getting in the way of the medical system. Second, you need to compare these oncosil sales to the rate of newly diagnosed LAPC in NZ. I think 2 in a quarter would be a high %. Third, there's no state reimbursement for oncosil in NZ (I think) as yet. Fourth, it shows that if clinicians become committed they will actually use it in preference to standard radiotherapy. I suspect the clinicians dealing with LAPC are a closer knit group in NZ which could help referral/uptake.
If that's replicated in other COVID normal markets it augers well.
Please - don;t lets complain about actual sales.
As for Osprey - watch out for the NZ group publishing their own experience first. Early adopters also want the kudos of publications and presentations. And that creates more evidence as well as momentum.
OSL Price at posting:
9.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)